although
research
mechan
viru
infect
carri
mani
section
scientif
commun
search
antivir
drug
almost
exclus
provinc
pharmaceut
manufactur
reason
partli
histor
chiefli
facil
run
largescal
screen
program
expens
met
commerci
occasion
government
resourc
need
protect
discoveri
unauthor
exploit
good
deal
secreci
inevit
surround
work
carri
commerci
organ
secreci
regrett
necessari
sinc
surviv
organ
depend
larg
get
fair
financi
return
money
invest
research
secur
aspect
commerci
research
natur
restrict
frank
construct
discuss
competitor
well
third
parti
particularli
true
antivir
research
perhap
revolt
enforc
isolation
led
least
part
first
confer
antivir
substanc
held
new
york
academi
scienc
manufactur
disclos
mani
detail
antivir
research
chanc
discuss
failur
compar
success
whippl
sinc
number
review
progress
field
antivir
chemothrrapi
appear
comment
recommend
ivhich
indic
radic
rethink
take
place
prospect
antivir
drug
osden
mcfadzean
goz
prusoff
swallow
natur
earli
espect
antivir
drug
would
discoverrd
would
analog
antibacteri
antibiot
darl
prrviou
decad
experi
date
prove
br
case
despit
prodigi
effort
drug
hous
three
clinic
use
antivir
agent
far
perfect
emerg
believ
thcre
lesson
learn
disappoint
record
hope
follow
remark
may
help
continu
critic
reapprais
field
futur
progress
may
faster
embark
search
antivir
drug
number
point
must
consid
order
assess
thr
technic
feasibl
treat
prevent
viru
disras
uith
drug
often
past
massiv
screen
bccn
set
mani
virus
hope
drug
would
turn
would
find
natur
place
human
veterinari
medicin
although
true
random
screen
still
offer
best
chanc
discov
new
drug
unless
realist
apprais
whole
project
made
outset
product
random
screen
could
well
useless
potenti
medicin
somr
import
considcr
list
diseas
econom
import
n
ordcr
commerci
viabl
drug
must
sell
suffici
quantiti
pay
devclopmcnt
manufactur
well
futur
research
antivir
chemic
tend
inhibit
specif
virus
diseas
low
incid
loneconom
import
rule
primari
target
drug
devclop
may
seem
inhuman
particularli
field
human
viru
diseas
fact
remain
easier
find
drug
rabi
influenza
sale
specif
antirabi
drug
would
never
cover
developmrnt
cost
diseas
loiv
incid
low
cconom
import
matter
seriou
outcom
may
infect
individu
inevit
must
remain
subject
sponsor
research
nevertheless
treatment
diseas
may
emerg
drug
develop
major
diseas
b
immunolog
control
mani
viru
diseas
human
anim
success
control
vaccin
success
natur
led
improv
spectrum
durat
protect
offer
vaccin
today
difficult
see
antivir
drug
could
compet
vaccin
control
mani
viru
diseas
exampl
one
may
cite
smallpox
yellow
fever
polio
recent
measl
among
human
diseas
newcastl
diseas
marek
diseas
infecti
bronchiti
among
poultri
diseasesan
area
veterinari
diseas
control
vaccin
particularli
import
despit
triumph
vaccin
probabl
never
complet
answer
control
certain
viru
diseas
area
drug
would
use
diseas
effort
concentr
two
import
human
diseas
class
influenza
common
cold
novel
strain
influenza
appear
among
human
popul
happen
exist
immun
previou
current
influenza
strain
effect
widespread
epidem
diseas
occur
diseas
spread
rapidli
first
appear
possibl
develop
distribut
administ
vaccin
base
new
strain
soon
enough
protect
use
number
popul
even
initi
overwhelm
pandem
success
epidem
occur
diseas
penetr
pocket
commun
escap
infect
diseas
maintain
partli
continu
appear
suscept
juvenil
partli
spontan
antigen
modif
viru
enabl
overcom
previou
immun
partli
gener
declin
immun
individu
passag
time
initi
pandem
theoret
possibl
control
diseas
widespread
vaccin
practic
done
consequ
diseas
smoulder
commun
appear
isol
case
occasion
outbreak
epidem
condit
diseas
normal
exist
situat
rather
much
public
pandem
caus
greatest
econom
loss
industri
countri
overal
loss
great
britain
due
asian
influenza
pandem
estim
million
continu
loss
time
least
million
year
loss
europ
north
america
japan
similar
industri
commun
must
romparablr
fraction
diseas
could
prevent
drug
econom
benefit
would
enorm
loss
due
common
cold
compar
care
studi
lidwel
william
show
approxim
x
work
day
arc
lost
cach
year
great
britain
alon
common
cold
scvertheless
prospect
common
cold
vaccin
poor
larg
number
virus
known
caus
diseas
known
rhinovirus
kapikian
probabl
compar
number
yct
unclassifi
rhinovirus
grow
catalog
coronavirus
kapikian
select
virus
includ
myxovirus
adenovirus
herpcsvirus
tyrrel
isol
clinic
cold
serolog
divers
etiolog
agent
make
prospect
vaccin
poor
common
cold
must
therefor
consid
target
even
though
difficult
target
antivir
drug
besid
problem
antigen
variat
exemplifi
influenza
thc
multipl
serotyp
exemplifi
common
cold
two
problem
associ
control
respiratori
diseas
parmter
administ
vaccin
first
circul
antibodi
appear
small
amount
respiratori
mucu
consequ
degre
protect
afford
respiratori
tract
less
shorter
durat
might
expect
second
problem
brought
light
use
experiment
vaccin
respiratori
syncyti
viru
diseas
infant
infant
vaccin
parenter
diseas
contract
natur
diseas
ill
infant
receiv
vaccin
reason
seem
circul
antibodi
result
parenter
vaccin
offer
littl
protect
respiratori
tract
natur
infect
occur
antibodi
combin
viru
antigen
surfac
respiratori
epitheli
ccll
caus
inflammatori
respons
correspond
increas
sever
clinic
symptom
kim
et
al
kapikian
et
al
chanock
et
point
immunopatholog
process
involv
serum
antibodi
occur
respiratori
syncyti
viru
infect
stimul
local
respiratori
tract
secretori
antibodi
intranas
instil
live
inactiv
viru
may
give
adequ
protect
without
unwant
hyperreact
similar
allerg
reaction
viru
antigen
preexist
antibodi
factor
possibl
major
factor
patholog
process
initi
herpesvirus
jone
patterson
mark
herp
diseas
possibl
candid
antivir
drug
develop
one
factor
deserv
care
consider
usual
receiv
way
potenti
antivir
drug
would
administ
anim
patient
requir
protect
clearli
common
cold
treatment
would
unaccept
given
intraven
time
day
less
obviou
less
real
difficulti
dose
larg
herd
cattl
sheep
effect
protect
maintain
freerang
anim
durat
protect
singl
dose
would
need
prolong
offset
labor
administ
dose
also
easier
dose
herd
inject
mouth
certain
veterinari
antivir
drug
may
requir
oral
activ
formul
convers
oral
dose
prefer
addit
food
drink
water
conveni
way
dose
poultri
onset
symptom
viru
diseas
acut
may
first
indic
host
contract
infect
usual
assum
antivir
drug
valu
prevent
cure
viru
diseas
nevertheless
although
period
viru
growth
infect
individu
may
short
may
well
long
enough
allow
use
therapi
exampl
et
al
shown
volunt
infect
intranas
coxsacki
viru
maximum
viru
growth
preced
onset
symptom
hour
work
may
seen
consider
amount
viru
growth
concurr
period
overt
symptom
applic
antivir
drug
period
day
might
well
prevent
full
develop
diseas
work
dougla
et
al
volunt
show
similar
period
exist
acut
rhinoviru
infect
dawkin
et
al
wingfield
et
al
shown
cours
influenza
human
modifi
even
onset
symptom
treatment
hardli
seem
necessari
point
undertak
search
drug
particular
diseas
etiolog
agent
diseas
unequivoc
identifi
number
import
viru
diseas
caus
agent
either
unknown
doubt
exampl
bovin
pneumonia
human
epidem
viral
gasteroenter
would
mistak
set
screen
agent
suspect
implic
diseas
case
subsequ
work
demonstr
fact
caus
agent
although
difficult
predict
chang
government
legisl
toward
public
anim
health
nevertheless
exist
prospect
legal
posit
variou
countri
consid
sinc
may
affect
prospect
potenti
drug
exampl
great
britain
foot
mouth
diseas
control
polici
slaughter
compens
countri
diseas
control
vaccin
lattrr
countri
drug
may
find
readi
market
legisl
chang
market
would
lost
summari
may
say
embark
search
antivir
drug
target
diseas
must
care
select
consider
relev
factor
import
thesc
r
must
adequ
market
drug
effect
immunolog
control
prospect
due
regard
given
practic
time
etiolog
diseas
clearli
establish
relev
factor
eg
medic
veterinari
legisl
takcn
consider
tabl
number
viru
diseas
econom
import
list
togeth
comment
illustr
mani
seemingli
attract
drugtarget
diseas
fact
preclud
factor
control
dose
patient
anim
risk
easi
list
properti
ideal
antivir
drugwid
spectrum
activ
nontox
access
target
organ
etc
easi
predict
sort
properti
one
might
expect
antivir
lead
detect
screen
program
intellig
attempt
screen
may
design
detect
compound
one
day
may
lead
develop
use
medicin
scientif
literatur
abound
report
antivir
chemic
discov
screen
random
compound
tissu
cultur
system
frequent
compound
turn
fals
posit
activ
rel
unimport
viru
product
tissu
cultur
screen
potenti
valu
screen
must
meet
requir
outlin
first
screen
abl
process
larg
number
chemic
compound
ferment
product
sinc
test
greater
chanc
success
find
activ
lead
perhap
time
come
new
drug
design
synthes
entir
ration
ground
present
activ
lead
chanc
discoveri
buthala
quot
compound
test
tissu
screen
show
antivir
activ
experi
rate
vari
ool
higher
rate
refer
influenza
virus
lower
rate
picornavirus
bauer
suggest
larger
viru
suscept
inhibit
sinc
given
intracellular
concentr
drug
larg
viru
encompass
physic
term
synthet
requir
drug
molecul
small
one
undoubtedli
principl
contribut
observ
high
rate
inhibit
influenza
viru
anoth
import
factor
seem
adsorpt
influenza
virus
cellular
receptor
particularli
vulner
interfer
extran
substanc
given
fraction
percent
compound
test
tissu
cultur
show
activ
small
proport
show
activ
anim
model
realist
screen
rate
would
less
compound
year
rate
less
chanc
find
use
compound
becom
small
make
whole
project
worthwhil
mani
publish
screen
procedur
viru
screen
run
seem
chosen
eas
handl
rather
relev
viru
diseas
target
exampl
ehrlich
et
al
describ
screen
primari
test
virus
includ
parainfluenza
type
measl
polioviru
johnson
describ
screen
includ
pseudorabi
adenoviru
mous
hepat
viru
cours
widespectrum
lead
appear
choic
test
viru
may
irrelev
antivir
compound
distinct
interferon
induc
known
present
character
rel
limit
spectrum
activ
eg
methisazon
activ
poxvirus
bauer
sadler
possibl
adenovirus
bauer
apostolov
laminoadamantan
activ
influenza
myxoor
paramyxovirus
davi
et
al
guanidin
ahydroxybenzyl
benzimidazol
activ
picornavirus
small
ribonucl
acid
rna
virus
egger
tamm
thu
whenev
possibl
virus
use
routin
screen
respons
clinic
largescal
screen
use
larg
number
tissu
cultur
cell
inevit
trend
toward
use
continu
cell
line
screen
procedur
cell
mani
attract
featur
grow
rapidli
easili
obtain
larg
quantiti
remain
year
year
madr
prrform
use
technic
trick
rapidli
chang
ph
medium
surviv
long
period
agar
perhap
import
support
growth
wide
rang
virus
continu
cell
line
seem
natur
choic
run
routin
screen
xevertheless
worthwhil
rememb
mani
desir
technic
properti
exhibit
cell
may
direct
result
neoplast
natur
use
continu
rather
primari
diploid
cell
tissu
cultur
system
take
yet
anoth
step
away
natur
diseas
truc
antivir
agent
laminoadamantan
methisazon
shown
protect
human
viru
diseasc
also
exert
antivir
action
neoplast
cell
tissu
cultur
exampl
hela
kb
cell
strike
evid
may
alway
follow
recent
discov
famili
chemic
compound
high
activ
rhinovirus
grown
human
diploid
lung
cell
virtual
activ
virusc
grow
monkey
kidney
cell
hela
cell
kb
cell
bucknal
unpublish
result
compound
other
may
exhibit
properti
would
miss
test
carri
continu
cell
line
summari
tissu
cultur
screen
abl
proccss
larg
number
tcst
compound
use
virus
relev
possibl
diseas
drug
requir
employ
normal
rather
neoplast
cell
unfortun
publish
screen
procedur
last
two
requir
sacrif
technic
consider
design
increas
number
compound
test
follow
descript
show
simplest
form
test
antivir
activ
involv
treat
cultur
cell
rang
concentr
test
compound
first
maximum
concentr
toler
ccll
assess
second
growth
viru
lowcr
concentr
compound
cytotox
measur
sever
ingeni
method
devis
measur
two
responsescytotox
viru
growthal
design
facilit
screen
larg
number
compound
exampl
herrmann
et
al
devis
zoneinhibit
test
larg
flat
dish
chicken
cell
infect
test
viru
overlaid
agar
contain
vital
stain
paper
disc
impregn
test
compound
place
surfac
agar
compound
antivir
activ
show
two
concentr
zone
around
paper
disc
innermost
pale
color
due
destruct
host
cell
cytotox
concentr
compound
diffus
disc
outsid
deepli
stain
zone
cell
expos
nontox
concentr
compound
also
protect
destruct
effect
viru
infect
beyond
concentr
compound
low
protect
cell
cell
sheet
destroy
viru
stain
poorli
thu
visual
inspect
dish
day
activ
compound
could
quickli
detect
rada
et
al
devis
similar
agar
diffus
test
test
compound
appli
virusinfect
cell
sheet
circular
well
agar
overlay
although
agar
diffus
test
capabl
process
larg
number
test
compound
suffer
two
drawback
first
compar
low
sensit
detect
cytotox
antivir
level
compound
second
limit
virus
produc
plaqu
agar
rightsel
et
al
devis
system
base
fact
cell
damag
either
toxic
effect
chemic
compound
viru
growth
would
swing
ph
medium
thu
incub
virusinfect
cell
seri
concentr
compound
look
cultur
chang
color
phenol
red
indic
medium
pink
yellow
activ
compound
could
detect
techniqu
also
use
assay
neutral
antibodi
interferon
action
pauker
finter
describ
system
wherebi
cytotox
effect
test
compound
could
assay
reduct
amount
neutral
red
taken
treat
cell
similarli
cytopath
effect
viru
growth
could
quantit
measur
reduct
uptak
neutral
red
infect
cell
system
readili
adapt
screen
test
compound
antivir
activ
myxovirus
use
system
cytopath
effect
may
pronounc
growth
best
monitor
reduct
neutral
red
uptak
quantit
hemadsorpt
method
match
neutral
red
uptak
method
accuraci
sensit
finter
contrast
eoneinhibit
phswing
test
neutral
red
uptak
test
precis
oper
may
use
demonstr
fine
differ
rel
toxic
activ
test
compound
probabl
timeconsum
former
test
system
test
antivir
agent
base
inhibit
nucleic
acid
synthesi
dcscribcd
lliller
et
al
use
screen
compound
mold
metabolit
antivir
activ
miller
et
ul
test
hela
cell
suspend
medium
contain
test
compound
toxic
effect
hela
cell
cellular
r
synthesi
measur
u
r
nh
fixat
reduc
similarli
cell
infect
r
viru
treat
sctinomycin
r
synthesi
due
viru
growth
thu
test
compound
reduc
virusdirect
rxa
synthesi
concentr
affect
cellular
r
synthesi
compound
exert
specif
effect
viru
growth
test
also
use
deoxyribonucl
acid
dsa
virus
cellular
viru
dxa
synthesi
monitor
includ
thmidineh
medium
viru
dsa
synthesi
distinguish
cellular
dsa
synthesi
disrupt
cell
end
test
treat
dcoxyribonucleas
encapsul
viru
dsa
resist
digest
unprotect
host
cell
dsa
thu
select
effect
test
compound
synthesi
viru
dsa
measur
author
claim
system
oper
satisfactorili
ivith
rang
virusessom
import
diseas
organismsand
simpl
reliabl
rapid
chief
critic
method
nucleic
acid
synthesi
use
sole
measur
viru
growth
test
compound
might
act
subsequ
stage
viru
replic
cycl
may
detect
exampl
disturb
sequenc
viru
nucleic
acid
inhibit
structur
protein
synthesi
failur
assembl
releas
matur
virion
would
provid
sound
basi
use
drug
phenomena
may
detect
type
test
also
sinc
high
infect
dose
viru
use
give
satisfactori
oper
test
viru
particl
per
cell
test
may
rather
insensit
detect
antivir
activ
antivir
activ
broadest
sens
competit
either
level
cellular
membran
receptor
cnzymic
templat
level
thu
viru
use
initi
infect
less
effect
antivir
compound
like
although
factor
turn
highli
activ
compound
inact
one
may
well
obscur
low
level
activ
might
use
start
point
chemic
exploit
real
valu
miller
test
use
import
biochem
system
nucleic
acid
synthesi
monitor
toxic
manifest
test
compound
subject
discuss
furthrr
follow
section
refer
alreadi
made
four
method
measur
toxic
chemic
compound
tissu
cultur
cell
direct
cytopath
effect
vital
dye
uptak
metabol
activ
phswing
nucleic
acid
inhibit
shortag
method
nevertheless
inadequ
assess
compound
toxic
antivir
test
probabl
give
rise
fals
lead
singl
caus
discuss
compound
toxic
might
measur
must
first
defin
strictli
interfer
cellular
metabol
extran
compound
toxic
effect
stringent
tissu
cultur
test
lack
toxic
continu
normal
divis
growth
cell
presenc
extran
compound
howev
test
cumbersom
use
rapid
screen
procedur
simpler
less
critic
test
invari
use
primari
screen
undoubtedli
simplest
method
assess
compound
toxic
direct
microscop
examin
cell
cytopath
effect
subtl
morpholog
chang
necessari
observ
train
detect
chang
arbitrari
scale
must
devis
record
observ
simpl
requir
met
method
gener
success
may
object
system
would
unwork
larg
number
compound
screen
correspondingli
larg
number
microscop
examin
requir
given
good
lowpow
microscop
experienc
reader
fact
random
compound
test
show
antivir
activ
therefor
requir
cursori
examin
system
reliabl
fast
econom
author
laboratori
system
kind
use
year
possibl
one
worker
screen
hundr
compound
three
virus
week
found
system
compound
appear
toxic
lower
concentr
either
zone
diffus
dye
uptak
method
conclud
therefor
method
sensit
other
mention
detect
toxic
effect
compound
direct
microscop
assess
toxic
without
defici
method
seen
preliminari
determin
toxic
defici
seriou
chief
among
appli
even
indirect
method
occasion
failur
detect
certain
type
toxic
exampl
time
time
compound
appear
prevent
viru
growth
show
toxic
confluent
sheet
tissu
cultur
cell
cultur
look
normal
sever
day
presenc
compound
virus
would
grow
cell
nevertheless
studi
see
shown
compound
exert
inhibitori
effect
aspect
cellular
metabol
prevent
viru
growth
investig
effect
inhibitor
nucleic
acid
synthesi
b
uncoupl
oxid
phosphoryl
two
class
compound
particularli
prone
give
mislead
result
nucleic
acid
inhibitor
often
slow
produc
cytopath
effect
confluent
monolay
cultur
cell
synthrsi
cell
low
suffici
r
synthesi
often
maintain
presenc
partial
effect
concentr
inhibitor
enabl
cellular
structur
integr
sustain
invad
viru
unabl
replic
cell
reduc
circumst
lead
appar
antivir
specif
mechan
chlorin
ribofuranosylbenzimidazol
exert
antivir
effect
bucknal
compound
extens
studi
antivir
agent
activ
found
specif
viru
tamm
et
al
tamm
srme
tamm
overman
uncoupl
oxid
phosphoryl
also
often
appear
antivir
agent
becausc
concentr
greatli
reduc
energygener
system
cell
confluent
monolay
often
slow
produc
morpholog
chang
halfpoison
state
cultur
appear
normal
support
viru
growth
thu
anoth
fals
lead
compound
gener
mention
earlier
remark
appli
tissu
cultur
system
greater
lesser
extent
tissu
cultur
test
antivir
activ
must
alway
regard
strictli
preliminari
activ
lead
test
must
alway
subject
closest
scrutini
determin
whether
activ
truli
specif
viruscod
process
simpli
result
subtl
toxic
effect
host
cell
margin
betwen
maximum
nontox
concentr
minimum
antivir
concentr
test
compound
conveni
express
thrrapcuti
ratio
max
nontox
concentrationmin
antivir
concentr
vari
accord
two
concentr
determin
simplest
stringent
test
maximum
nontox
concentr
compound
zdtro
grow
cell
presenc
compound
determin
maximum
concentr
divis
growth
proceed
normal
concentr
lower
one
protect
cell
viru
attack
unequivoc
demonstr
compound
exert
specif
effect
aspect
viru
replicat
ion
like
miller
et
al
found
inhibit
cellular
nucleic
acid
synthesi
particularli
r
synthesi
use
system
detect
toxic
effect
test
compound
cell
treat
rang
concentr
compound
uptak
r
n
e
h
acidinsolubl
materi
measur
compar
normal
cell
bucknal
test
simpl
run
sinc
nucleic
acid
metabol
cardin
area
cellular
metabol
even
compound
direct
effect
nucleic
acid
synthesi
disturb
synthet
homeostat
mechan
quickli
reflect
chang
synthesi
rna
dna
fig
doserespons
curv
one
experiment
compound
determin
human
diploid
lung
cell
three
method
outlin
abovedirect
cytopath
effect
confluent
monolay
inhibit
rna
synthesi
inhibit
cell
growth
newli
seed
cultur
although
compound
specif
inhibitor
rna
synthesi
inhibit
rna
synthesi
product
cytopath
effect
run
close
togeth
concentr
indirectli
affect
nucleic
acid
synthesi
suffici
disturb
caus
area
cellular
metabol
lead
gener
cytopath
effect
cell
divis
affect
lower
concentr
particular
case
inhibitori
therefor
toxic
effect
detect
concentr
time
lower
caus
cell
destruct
nevertheless
even
cell
growth
measur
toxic
effect
cellular
growth
rate
higher
suppress
viru
growth
indic
ici
exert
specif
effect
viru
growth
end
point
cpe
pgml
rna
synthesi
pglml
cell
growth
pgml
viru
growth
pgml
clear
margin
toxic
antivir
effect
may
seen
viru
yield
curv
fusid
acid
report
show
specif
antivir
activ
tissu
cultur
acornley
et
al
also
test
way
fig
case
concentr
caus
cytopath
effect
hour
pgml
wherea
viru
yield
depress
pglml
give
appar
therapeut
ratio
effect
fusid
acid
cellular
synthesi
studi
clear
cellular
rka
synthesi
drastic
reduc
pg
ml
thu
fusid
acid
probabl
reduc
viru
growth
inhibit
cellular
rather
viru
synthet
process
probabl
account
fact
compound
show
clinic
use
effect
virusinfect
volunt
despit
good
level
drug
blood
nasal
secret
acornley
et
al
sinc
toxic
effect
compound
vitro
usual
increas
time
import
compar
toxic
antivir
activ
ensur
compound
contact
xvith
cell
length
time
case
experi
cytopath
effect
rna
synthesi
cell
growth
viru
inhibit
measur
cell
expos
compound
hour
viru
diseas
limit
particular
target
organ
respiratori
tract
great
valu
abl
cultur
portion
organ
vitro
studi
cultur
portibn
trachea
extens
use
studi
growth
respiratori
virus
hoorn
tyrel
mcintosh
et
al
craighead
brennan
herbstlaier
recent
organ
cultur
human
embryon
gut
use
studi
agent
human
viru
gastroenter
h
et
al
techniqu
could
presum
extend
studi
virus
polio
rabi
smallpox
herp
local
specif
organ
infect
individu
found
use
human
embryo
anim
tracheal
piec
valu
studi
toxic
antivir
activ
lead
produc
tissu
cultur
screen
program
techniqu
excis
trachea
cut
transvers
ring
mm
thick
place
x
tube
ml
eagl
medium
roll
exactli
convent
tissu
cultur
lowpow
microscop
ciliari
activ
respiratori
epithelium
assess
arbitrari
scale
presenc
test
compound
reduct
ciliari
action
highli
sensit
measur
compound
toxic
easi
determin
concentr
full
ciliari
activ
maintain
fig
lower
concentr
effect
viru
growth
may
measur
harvest
cultur
fluid
interv
titrat
infecti
viru
use
techniqu
found
almost
socal
activ
compound
produc
tissu
cultur
screen
influenza
appear
neg
test
ferret
tracheal
cultur
almost
case
compound
toxic
lower
concentr
tracheal
cultur
convent
tissu
cultur
monolay
judg
cessat
ciliari
activ
proport
compound
data
concern
biochem
action
avail
case
drug
uncoupl
oxid
phosphoryl
nucleic
acid
inhibitor
gener
antimetabolit
inhibit
ciliari
action
tracheal
cultur
therefor
much
sensit
index
toxic
effect
morpholog
chang
monolay
fig
ciliainhibitori
concentr
ici
pg
ml
effect
detect
concentr
time
lower
necessari
caus
morpholog
chang
convent
tissu
cultur
cell
fig
l
presum
metabol
pattern
ciliat
cell
complex
static
cell
cultur
therefor
readili
disturb
gener
concentr
compound
suppress
ciliari
activ
arc
compar
prevent
cell
growth
except
case
specif
inhibitor
dsa
synthesi
cell
divis
growth
usual
sensit
ciliari
activ
convent
techniqu
may
use
measur
viru
growth
antivir
testscytopath
effect
plaqu
reduct
yield
infecti
viru
htmadsorpt
bring
thc
common
thcir
simplic
cytopath
effect
hcmadsorpt
widdi
use
hut
techniqu
must
use
precaut
certain
type
antivir
activ
miss
order
speed
rate
antivir
test
quantiti
challeng
viru
often
increas
theoret
maximum
viru
particl
per
cell
whole
cell
cultur
behav
synchron
result
obtain
whatev
time
viru
take
complet
replic
cycleusu
hour
procedur
howev
test
compound
prevent
format
infecti
viru
unabl
protect
infect
cell
destruct
would
detect
exampl
rel
complex
viru
influenza
difficult
imagin
rna
synthesi
could
interrupt
hemagglutinin
product
continu
much
van
magnu
effect
result
would
monolay
show
full
hemadsorpt
yet
transmiss
viru
would
form
test
compound
produc
effect
would
great
interest
potenti
drug
could
miss
test
dose
challeng
viru
high
wherev
possibl
test
permit
sever
cycl
viru
growth
occur
compound
interrupt
part
cycl
may
detect
school
thought
tissu
cultur
test
artifici
littl
valu
detect
use
antivir
substanc
argu
test
antivir
effect
directli
anim
activ
detect
like
valid
use
detect
tissu
cultur
true
major
activ
compound
detect
tissu
cultur
screen
activ
anim
even
full
authent
antivir
activ
test
discuss
reason
usual
compound
reach
target
organ
suffici
amount
show
activ
rather
intrins
defect
antivir
activ
compound
also
apart
interferon
induc
unless
compound
manifest
activ
vitro
highli
unlik
vivo
one
hand
argu
viru
grow
tissu
cultur
cell
littl
relev
process
viru
caus
diseas
whole
anim
hand
said
sinc
viru
growth
basi
patholog
process
viru
growth
halt
diseas
stop
furthermor
literatur
disclos
highli
irrelev
virus
use
anim
test
system
even
human
pathogen
use
eg
influenza
requir
extens
adapt
anim
host
cours
diseas
usual
differ
human
final
conveni
anim
model
studi
growth
human
rhinoand
coronavirus
unless
tissu
cultur
test
use
could
screen
antivir
compound
import
pathogen
therefor
convinc
theoret
advantag
use
anim
routin
antivir
screen
togeth
cumbersom
natur
anim
test
difficulti
scalingup
test
larg
number
compound
make
tissu
cultur
test
attract
proposit
initi
screen
program
forego
remark
appli
cours
detect
compound
direct
effect
specif
viru
process
eg
absorpt
penetr
replic
field
interferon
induc
immun
enhanc
stimul
thr
host
defens
mechan
obvious
one
choic
use
test
anim
one
concern
detect
overal
rffcct
cours
diseas
rathrr
accur
model
particular
human
veterinari
infect
accordingli
choic
test
system
less
critic
provid
fulfil
certain
requir
instancc
thr
viru
test
compound
administ
separ
site
avoid
possibl
local
destruct
challeng
viru
test
compound
test
compound
given
parenter
give
best
chanc
absorpt
c
dose
challeng
viru
suffici
small
allow
use
incub
period
symptom
develop
follow
system
use
success
us
group
mice
dose
intraperiton
test
compound
mg
kg
four
success
day
twentyfour
hour
first
dose
challeng
intramuscularli
jild
semliki
forest
viru
last
dose
observ
symptom
twice
daili
mcan
rcciproc
day
death
mrdd
test
group
calcul
day
comparcd
similar
undos
group
w
l
l
group
givcn
four
daili
inject
protect
agent
polyinsiniepolyrytidilir
acid
poli
ic
figur
show
typic
respons
mice
treat
nith
poli
ic
untreat
control
particular
condit
respons
curv
overlap
select
mrdd
criterion
activ
theoret
inact
compound
test
appear
spuriou
activ
would
requir
retest
establish
true
statu
caution
need
interpret
convers
overlap
given
known
activ
compound
singl
activ
compound
test
time
test
everi
would
miss
compound
practic
vast
major
compound
pass
test
inact
chanc
occasion
true
activ
compound
chanc
fall
miss
categori
correspondingli
reduc
even
vivo
test
reduc
minimum
still
requir
larg
effort
term
manpow
facil
test
realist
number
compound
although
mani
human
virus
grow
anim
host
often
difficult
assess
potenti
valu
antivir
compound
human
use
use
anim
model
five
main
reason
first
rel
benign
human
viru
infect
often
follow
differ
often
sever
cours
anim
exampl
influenza
viru
herp
simplex
coxsacki
virus
may
caus
much
seriou
diseas
laboratori
anim
man
second
human
virus
often
must
adapt
multipl
passag
grow
satisfactorili
anim
host
therefor
challeng
viru
anim
model
may
differ
creatur
origin
human
pathogen
third
quantiti
viru
administ
anim
order
produc
measur
effect
eg
symptom
viru
isol
seroconvers
usual
vastli
greater
would
ordinarili
encount
natur
host
profound
bear
efficaci
cur
agent
exampl
finter
shown
protect
offer
mice
dose
interferon
greatli
increas
quantiti
challeng
viru
reduc
fourth
fate
drug
administ
anim
may
differ
seen
man
last
compound
may
show
toxio
effect
man
show
anim
last
two
point
probabl
import
determin
far
result
obtain
anim
model
relev
man
theori
consider
oper
direct
compound
show
posit
result
anim
model
may
posit
neg
man
compound
neg
anim
may
neg
posit
man
sinc
mani
anim
model
offer
greater
challeng
therapeut
potenti
drug
natur
diseas
man
posit
result
anim
model
alway
give
great
hope
posit
result
might
achiev
man
consider
often
encourag
evalu
potenti
antivir
drug
man
slimmest
ground
exampl
dilemma
anim
model
may
pose
afford
vork
boyl
colleagu
compound
skf
compound
shown
activ
number
virus
includ
wide
rang
human
rhinovirus
tissu
cultur
problem
aros
evalu
compound
vivo
smallanim
modrl
human
rhinoviru
infect
author
therefor
decid
test
compound
chimpanze
one
primat
suscept
human
rhinovirus
lack
knowledg
infect
human
rhinovirus
chimpanze
author
gave
ooo
tcd
challeng
viru
anim
ensurc
infcction
anim
given
drug
oral
time
day
cours
diseas
monitor
viru
shed
nose
rate
antibodi
rise
also
measur
number
anim
experi
necessarili
smallusu
treat
drug
control
final
result
tantalizingli
inconclus
clearli
neg
convincingli
posit
drug
produc
cur
effect
investig
admit
system
far
satisfactori
conclud
result
compound
northwhil
studi
human
subject
conclus
howev
would
probabl
reach
compound
clearli
inact
chimpanze
ground
excess
dose
challeng
viru
unknown
factor
chimpanze
metabol
could
led
result
anim
model
human
viru
diseas
must
best
regard
poor
imit
natur
condit
result
obtain
anim
model
whether
posit
neg
encourag
discourag
interprct
cautious
never
use
sole
basi
predict
outcom
man
research
treatment
viru
diseas
drug
present
direct
toward
three
gener
area
attempt
stimul
defens
mechan
host
anim
larg
screen
program
find
drug
directli
block
virusspecif
process
allevi
symptom
diseas
first
approach
exemplifi
varieti
interferon
induc
present
intens
studi
disappoint
featur
uniformli
low
activ
man
despit
highli
promis
result
laboratori
anim
mice
rat
rabbit
perhap
interferon
respons
man
primat
less
import
defens
viru
diseas
taxonom
group
search
made
gener
stimul
host
defens
mechan
exampl
stimul
phagocytosi
immun
respons
littl
progress
report
far
search
drug
directli
inhibit
viru
replic
stop
viruscod
synthet
process
absorpt
penetr
uncoat
assembl
releas
virion
intens
still
continu
nevertheless
product
effort
find
applic
rel
small
number
viru
diseas
reason
outlin
diseas
high
econom
import
effect
vaccin
avail
specif
antivir
drug
ever
commerci
realiti
present
pauciti
drug
undoubtedli
due
larg
intim
associ
virus
molecular
level
host
cell
reason
diseas
target
must
care
defin
screen
procedur
made
meaning
possibl
limit
anim
model
clearli
recogn
attent
detail
maximum
effort
brought
difficult
problem
lack
clinic
use
drug
allow
specul
possibl
drugresist
virus
emerg
antivir
drug
eventu
widespread
use
phenomenon
drug
resist
virus
well
establish
laboratori
melnick
et
al
tamm
egger
reni
buthala
unless
potenti
antivir
drug
free
seriou
defect
commerci
life
embarrassingli
short
treatment
symptom
rather
caus
diseas
mainstay
medic
practic
time
immemori
still
case
viru
diseas
short
incub
period
mani
viru
diseas
inevit
restrict
therapeut
use
antivir
drug
case
symptom
alreadi
appear
physician
layman
alik
recours
extens
armamentanurn
palli
avail
allevi
symptom
viru
diseas
clearli
unsatisfactori
state
affair
ultim
goal
antivir
research
prevent
viru
diseas
understand
virus
increas
ration
approach
chemotherapi
viru
diseas
becom
feasibl
also
random
discoveri
antivir
activ
novel
chemic
compound
shed
light
area
viru
metabol
suscept
chemic
attack
increas
contribut
approach
viru
chemotherapi
soon
emerg
theoret
possibl
practic
realiti
antivir
drug
ivil
make
long
await
contribut
clinic
medicin
